

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
PRIVACY	GUATEMALA	Day	Month	Year	7 Years	Female	Unk	Day	Month	Year	
<p>7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)            Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)</p> <p>I could not give her the injection last night [Drug dose omission by device]            locked and could not be unscrewed [Device mechanical jam]</p> <p>Case Description: This is a spontaneous report received from a Consumer or other non HCP, Program ID:            164974.</p> <p>A 7-year-old female patient received somatropin (GENOTROPIN PEN), since 09Oct2024 (Lot number:            HL8272, Expiration Date: Jul2026) at 0.8 mg daily. The patient's relevant medical history and concomitant            medications were not reported.</p> <p style="text-align: right;">(Continued on Additional Information Page)</p>											
<input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION  <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING											

14. SUSPECT DRUG(S) (include generic name) #1 ) Genotropin Pen (SOMATROPIN) Solution for injection {Lot # HL8272; Exp.Dt. JUL-2026} #2 ) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution for injection		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1 ) 0.8 mg, daily #2 )	16. ROUTE(S) OF ADMINISTRATION #1 ) Unknown #2 ) Unknown	21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
17. INDICATION(S) FOR USE #1 ) Unknown #2 ) Unknown		
18. THERAPY DATES(from/to) #1 ) 09-OCT-2024 / Unknown #2 ) Unknown	19. THERAPY DURATION #1 ) Unknown #2 ) Unknown	

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
Unknown		

24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San jose, COSTA RICA		26. REMARKS
24b. MFR CONTROL NO. <b>PV202500048789</b>	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	
24c. DATE RECEIVED BY MANUFACTURER 21-APR-2025		
24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous		
DATE OF THIS REPORT 24-APR-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

---

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

The following information was reported: DRUG DOSE OMISSION BY DEVICE (non-serious), described as "I could not give her the injection last night"; DEVICE MECHANICAL ISSUE (non-serious), described as "locked and could not be unscrewed". The action taken for somatropin was unknown.

Causality for "i could not give her the injection last night" and "locked and could not be unscrewed" was determined associated to device constituent of somatropin (malfunction).